Evidence map›Paper›PMID 40899434›Full record

ArticleBiotechnology journal2025

Enhanced Production of HCV E1E2 Subunit Vaccine Candidates via Protein-Protein Interaction Identification in Glycoengineered CHO Cells.

Mina Ying Min Wu, Frances Rocamora, Caressa M Robinson, Seunghyeon Shin, Svetlana Maurya, Eric A Toth, Thomas R Fuerst, Nathan E Lewis

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biotechnology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Deciphering the determinants of recombinant protein expression across the human secretome.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Mina Ying Min WuDepartment of Bioengineering, University of California, San Diego, La Jolla, California, USA.
Frances RocamoraDepartment of Pediatrics, University of California, San Diego, La Jolla, California, USA.
Caressa M RobinsonDepartment of Bioengineering, University of California, San Diego, La Jolla, California, USA.
Seunghyeon ShinDepartment of Pediatrics, University of California, San Diego, La Jolla, California, USA.
Svetlana MauryaSanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA.
Eric A TothInstitute for Bioscience and Biotechnology Research, University of Maryland, Rockville, Maryland, USA.
Thomas R FuerstInstitute for Bioscience and Biotechnology Research, University of Maryland, Rockville, Maryland, USA.
Nathan E LewisDepartment of Bioengineering, University of California, San Diego, La Jolla, California, USA.ORCID https://orcid.org/0000-0001-7700-3654

Funding

Rational design and efficacy testing of vaccines against HCVR01AI168048 · NIAID · UNIV OF MARYLAND, COLLEGE PARK · PI Alexander Andrianov, Thomas R Fuerst · 2022 to 2026
$7.1M
Unraveling the mammalian secretory pathway through systems biology and algorithm developmentR35GM119850 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LEWIS, NATHAN ENOCH · 2016 to 2025
$4.3M
NIAID NIH HHS R01 AI168048NIGMS NIH HHS R35 GM119850NIH HHS R01 AI132212NIH HHS R01 AI168048NIH HHS R35 GM119850Novo Nordisk Foundation NNF20SA0066621NSF CBET-2030039
6 · The paper itself

Abstract

Hepatitis C Virus (HCV) is a pervasive bloodborne virus and the leading cause of chronic liver disease and cancer. Thus, the development of an HCV vaccine is of great importance. Prior work has developed candidate vaccines, including more potent glycoengineered viral proteins and secreted forms of the E1E2 envelope heterodimer (sE1E2). However, efforts to express them recombinantly in Chinese hamster ovary (CHO) cells have resulted in very low titers. To address this challenge, here we employed a multi-omics approach to identify protein interactors that may enhance the secretion of an sE1E2 vaccine candidate. We detected protein-protein interactions (PPIs) using the Biotinylation by Antibody Recognition (BAR) assay and integrated these data with RNA-Seq. Through this, we identified and overexpressed proteins that interact with sE1E2 in CHO cells. Among these, CUL4A and YWHAH enhanced sE1E2 secretion in our glycoengineered CHO cells. The integration of omics techniques and genetic engineering in this study provides valuable insights into the host cell proteins that interact with the HCV E1E2 heterodimer, and how they may be harnessed to improve protein secretion in CHO cells to enable more affordable and accessible biotherapeutics.

Indexed as

HepacivirusViral Envelope ProteinsViral Hepatitis VaccinesAnimalsCHO CellsCricetulusHumansRecombinant ProteinsVaccines, SubunitE1 protein, Hepatitis C virusglycoprotein E2, Hepatitis C virusRecombinant ProteinsVaccines, SubunitViral Envelope ProteinsViral Hepatitis Vaccineshepatitis C vaccineprotein‐protein interactionsproteomics

Identifiers

PMID40899434
PMCPMC12435534

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.